The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Open accessAbstract
BACKGROUND: Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in several cancer types. METHODS: We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-1, and PD-L1 and pyrosequencing for assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status in 135 glioblastoma specimens (117 initial resection, 18 first local recurrence). PD-L1 gene expression was analyzed in 446 cases from The Cancer Genome Atlas. RESULTS: Diffuse/fibrillary PD-L1 expression of variable extent, with or without interspersed epithelioid tumor cells with membranous PD-L1 expression, was observed in 103 of 117 (88.0%) newly diagnosed and 13 of 18 (72.2%) recurrent glioblastoma specimens. Sparse-to-moderate density of tumor-infiltrating lymphocytes (TILs) was found in 85 of 117 (72.6%) specimens (CD3+ 78/117, 66.7%; CD8+ 52/117, 44.4%; CD20+ 27/117, 23.1%; PD1+ 34/117, 29.1%). PD1+ TIL density correlated positively with CD3+ (P < .001), CD8+ (P < .001), CD20+ TIL density (P < .001), and PTEN expression (P = .035). Enrichment of specimens with low PD-L1 gene expression levels was observed in the proneural and G-CIMP glioblastoma subtypes and in specimens with high PD-L1 gene expression in the mesenchymal subtype (P = 5.966e-10). No significant differences in PD-L1 expression or TIL density between initial and recurrent glioblastoma specimens or correlation of PD-L1 expression or TIL density with patient age or outcome were evident. CONCLUSION: TILs and PD-L1 expression are detectable in the majority of glioblastoma samples but are not related to outcome. Because the target is present, a clinical study with specific immune checkpoint inhibitors seems to be warranted in glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Adjusting for multiple testing—when and how?
Bender, R., & Lange, S. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00314-0 · Cited by 3,004
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Self-citationTaube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
The transcriptional network for mesenchymal transformation of brain tumours
Carro, M. S., Lim, W. K., Alvarez, M. J., Bollo, R. J., Zhao, X., Snyder, E. Y., Sulman, E. P., Anne, S. L., Doetsch, F., Colman, H., et al. (2010) · Nature · doi:10.1038/nature08712 · Cited by 1,259
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
Mu, C.-Y., Huang, J.-A., Chen, Y., Chen, C., & Zhang, X.-G. (2011) · Medical Oncology · doi:10.1007/s12032-010-9515-2 · Cited by 577
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535 · cited 2×
“However, responses to PD-1/PD-L1 inhibitors are observed in a significant fraction of patients with PD-L1 negative tumor samples, and the true predictive value of PD-L1 expression is under intense investigation in ongoing clinical trials.(15,37) An association of PD-L1 expression and PTEN loss via PI3K/ AKT pathway si…”
BackgroundResultCurrent concepts and management of glioblastoma
Preusser, M., de Ribaupierre, S., Wöhrer, A., Erridge, S. C., Hegi, M., Weller, M., & Stupp, R. (2011) · Annals of Neurology · doi:10.1002/ana.22425 · Cited by 461
Self-citationBloch, O., Crane, C. A., Kaur, R., Safaee, M., Rutkowski, M. J., & Parsa, A. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3314 · Cited by 458
Prins, R. M., Soto, H., Konkankit, V., Odesa, S. K., Eskin, A., Yong, W. H., Nelson, S. F., & Liau, L. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2563 · Cited by 451
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
PD‐1 as a potential target in cancer therapy
McDermott, D. F., & Atkins, M. B. (2013) · Cancer Medicine · doi:10.1002/cam4.106 · Cited by 414
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Xu, C., Fillmore, C. M., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 391
Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M., & Wiendl, H. (2003) · PubMed · Cited by 381
Self-citationWintterle, Schreiner, Mitsdoerffer, Schneider, Chen, Meyermann, Weller, M., & Wiendl (2003) · 中国神经肿瘤杂志 · Cited by 366
Self-citationMuenst, S., Soysal, S. D., Gao, F., Obermann, E. C., Oertli, D., & Gillanders, W. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2581-3 · Cited by 334
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M., Avramis, E., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 334
PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3
Wölfle, S. J., Strebovsky, J., Bartz, H., Sähr, A., Arnold, C., Kaiser, C., Dalpke, A. H., & Heeg, K. (2011) · European Journal of Immunology · doi:10.1002/eji.201040979 · Cited by 323
Song, M., Chen, D., Lu, B., Wang, C., Zhang, J., Huang, L., Wang, X., Timmons, C. L., Hu, J., Liu, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065821 · Cited by 266
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Reifenberger, G., Hentschel, B., Felsberg, J., Schackert, G., Simon, M., Schnell, O., Westphal, M., Wick, W., Pietsch, T., Loeffler, M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27385 · Cited by 252
Self-citationDahlin, A. M., Henriksson, M. L., Van Guelpen, B., Stenling, R., Öberg, Å., Rutegård, J., & Palmqvist, R. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.234 · Cited by 228
Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas
Doucette, T., Rao, G., Rao, A., Shen, L., Aldape, K., Wei, J., Dziurzynski, K., Gilbert, M., & Heimberger, A. B. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0028 · Cited by 226
Rutledge, W. C., Kong, J., Gao, J., Gutman, D. A., Cooper, L. A. D., Appin, C., Park, Y., Scarpace, L., Mikkelsen, T., Cohen, M. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0551 · Cited by 200
Wöhrer, A., Waldhör, T., Heinzl, H., Hackl, M., Feichtinger, J., Gruber-Mösenbacher, U., Kiefer, A., Maier, H., Motz, R., Reiner-Concin, A., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9938-9 · Cited by 189
Self-citationTumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
Boland, J. M., Kwon, E. D., Harrington, S. M., Wampfler, J. A., Tang, H., Yang, P., & Aubry, M. C. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.05.006 · Cited by 185
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
Kreisl, T. N., Lassman, A. B., Mischel, P. S., Rosen, N., Scher, H. I., Teruya-Feldstein, J., Shaffer, D., Lis, E., & Abrey, L. E. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9741-z · Cited by 176
Wen, P. Y., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not247 · Cited by 171
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
Liu, Y., Carlsson, R., Ambjørn, M., Hasan, M., Badn, W., Darabi, A., Siesjö, P., & Issazadeh‐Navikas, S. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5812-12.2013 · Cited by 151
Yang, I., Han, S. J., Sughrue, M. E., Tihan, T., & Parsa, A. T. (2011) · Journal of neurosurgery · doi:10.3171/2011.4.jns101172 · Cited by 146
PTEN methylation and expression in glioblastomas
Baeza, N., Weller, M., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0748-4 · Cited by 139
Self-citationEfficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
Queirolo, P., Spagnolo, F., Ascierto, P. A., Simeone, E., Marchetti, P., Scoppola, A., Vecchio, M. D., Guardo, L. D., Maio, M., Giacomo, A. M. D., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1400-y · Cited by 120
Immunotherapy for Brain Cancer: Recent Progress and Future Promise
Jackson, C. M., Lim, M. K., & Drake, C. G. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2057 · Cited by 104
Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model
Tran, T.-T., Uhl, M., Jing, Y., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-010 · Cited by 96
Doucette, T. A., Kong, L.-Y., Yang, Y., Ferguson, S. D., Yang, J., Wei, J., Qiao, W., Fuller, G. N., Bhat, K., Aldape, K., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos139 · Cited by 93
Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma
Rodríguez, F. J., Scheithauer, B. W., Giannini, C., Bryant, S. C., & Jenkins, R. B. (2008) · Cancer · doi:10.1002/cncr.23899 · Cited by 92
Glial cells suppress postencephalitic CD8 + T lymphocytes through PD‐L1
Schachtele, S. J., Hu, S., Sheng, W. S., Mutnal, M. B., & Lokensgard, J. R. (2014) · Glia · doi:10.1002/glia.22701 · Cited by 87
Butowski, N. A., Chang, S. M., Lamborn, K. R., Polley, M.-Y., Pieper, R. O., Costello, J., VandenBerg, S. R., Parvataneni, R., Nicole, A., Sneed, P. K., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor130 · Cited by 77
Pittet, C. L., Newcombe, J., Antel, J. P., & Arbour, N. (2011) · Glia · doi:10.1002/glia.21158 · Cited by 67
Preusser, M., Berghoff, A. S., Manzl, C., Filipits, M., Weinhäusel, A., Pulverer, W., Dieckmann, K. U., Widhalm, G., Wöehrer, A., Knosp, E., et al. (2013) · Clinical Neuropathology · doi:10.5414/np300730 · Cited by 54
Self-citationHan, S. J., Ahn, B. J., Waldron, J. S., Yang, I., Fang, S., Crane, C. A., Pieper, R. O., & Parsa, A. T. (2009) · Neuroreport · doi:10.1097/wnr.0b013e32833188f7 · Cited by 43
Durand-Panteix, S., Farhat, M., Youlyouz‐Marfak, I., Rouaud, P., Ouk, C., David, A., Faumont, N., Feuillard, J., & Jayat‐Vignoles, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102277 · Cited by 43
Cited by
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Cancer Research Communications
(2021) · doi:10.1158/1078-0432 · Cited by 1,532
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Self-citationHendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
Self-citationMolecular targeted therapy of glioblastoma
Le Rhun, E., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M., Wen, P., Reifenberger, G., & Weller, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101896 · Cited by 688
Self-citation
Metadata
- Authors
- Berghoff, A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., Kurscheid, S., Hegi, M. E., Zielinski, C. C., Marosi, C., Hainfellner, J. A., Preusser, M., & Wick, W.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-10-29
- Volume
- 17
- Issue
- 8
- Pages
- 1064-1075
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2116371946
- Cited by
- 585
- References
- 54
- FWCI
- 19.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.